Abstract
The inhibition of Histamine N-methyltransferase (HNMT) has been recently shown to play potential roles in the treatment of neurodegenerative diseases, allergic vasoconstriction and anaphylactic manifestation. For designing and discovering new potential human HNMT inhibitors, the ligand (Hypo1) and structure-based (SB_Hypo1) pharmacophore models were developed based on the most active inhibitors and the highest resolution crystal structure of HNMT, respectively. After validating the reliability of both models with decoy dataset, they were separately used as 3D-query for virtual screening to retrieve potential hits from Maybridge and Chembridge databases. Subsequently, the hit compounds were subjected to filter by applying the ADMET, molecular docking and consensus score. Finally, 10 hits (five compounds from each model) were suggested as potential leads based on the structural diversity, good fit value, favorable binding interactions and high docking consensus score. The obtained novel hits from this study may facilitate to identify and optimize new leads for HNMT inhibition.
Keywords: Consensus scoring, Histamine N-methyltransferase, HipHop, Molecular docking, Structurebased, Virtual screening, Ligand, pharmacophore modeling, Histamine, Hypo1, HNMT, 3D-query, Chembridge databases, ADMET, GPCR, HDC
Letters in Drug Design & Discovery
Title: Ligand and Structure-Based Pharmacophore Modeling for the Discovery of Potential Human HNMT Inhibitors
Volume: 9 Issue: 1
Author(s): Pavadai Elumalai, Hsuan-Liang Liu, Zheng-Li Zhou, Jian-Hua Zhao, Wilson Chen, Chih-Kuang Chuang, Wei-Bor Tsai and Yih Ho
Affiliation:
Keywords: Consensus scoring, Histamine N-methyltransferase, HipHop, Molecular docking, Structurebased, Virtual screening, Ligand, pharmacophore modeling, Histamine, Hypo1, HNMT, 3D-query, Chembridge databases, ADMET, GPCR, HDC
Abstract: The inhibition of Histamine N-methyltransferase (HNMT) has been recently shown to play potential roles in the treatment of neurodegenerative diseases, allergic vasoconstriction and anaphylactic manifestation. For designing and discovering new potential human HNMT inhibitors, the ligand (Hypo1) and structure-based (SB_Hypo1) pharmacophore models were developed based on the most active inhibitors and the highest resolution crystal structure of HNMT, respectively. After validating the reliability of both models with decoy dataset, they were separately used as 3D-query for virtual screening to retrieve potential hits from Maybridge and Chembridge databases. Subsequently, the hit compounds were subjected to filter by applying the ADMET, molecular docking and consensus score. Finally, 10 hits (five compounds from each model) were suggested as potential leads based on the structural diversity, good fit value, favorable binding interactions and high docking consensus score. The obtained novel hits from this study may facilitate to identify and optimize new leads for HNMT inhibition.
Export Options
About this article
Cite this article as:
Elumalai Pavadai, Liu Hsuan-Liang, Zhou Zheng-Li, Zhao Jian-Hua, Chen Wilson, Chuang Chih-Kuang, Tsai Wei-Bor and Ho Yih, Ligand and Structure-Based Pharmacophore Modeling for the Discovery of Potential Human HNMT Inhibitors, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192955
DOI https://dx.doi.org/10.2174/157018012798192955 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Contribution of Stem Cells to Kidney Repair
Current Stem Cell Research & Therapy New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Regulation of Hemostasis by Singlet-Oxygen (1ΔO2*)
Current Vascular Pharmacology TRP Channels as Targets for Therapeutic Intervention in Obesity: Focus on TRPV1 and TRPM5
Current Topics in Medicinal Chemistry Regulation of Foxo-Dependent Transcription by Post-Translational Modifications
Current Drug Targets Proteomic Analysis of Neutrophil Priming by PAF
Protein & Peptide Letters Probiotics and Oral Health
Current Pharmaceutical Design Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
Current Gene Therapy Medicinal Treatments of Cholesterol Gallstones: Old, Current and New Perspectives
Current Medicinal Chemistry Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design